Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US-2015376115-A1 · Dec 31, 2015 · US
US9376372B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9376372-B2 |
| Application number | US-201314412633-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 8, 2013 |
| Priority date | Jul 6, 2012 |
| Publication date | Jun 28, 2016 |
| Grant date | Jun 28, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides processes for producing amine compounds. The amine compounds include diammonium compounds and amino acid derivatives.
Opening claim text (preview).
The invention claimed is: 1. A process for producing an amino acid salt or derivative thereof comprising the steps of: providing an unsaturated amine salt or derivative thereof; and wherein the unsaturated amine salt is a compound of Formula I wherein each R 1 is independently selected from the group consisting of H, optionally C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 2 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 2 -C 12 heterocycloalkenyl, optionally substituted C 6 -C 18 aryl, optionally substituted C 1 -C 18 heteroaryl, optionally substituted C 1 -C 12 alkyloxy, optionally substituted C 2 -C 12 alkenyloxy, optionally substituted C 2 -C 12 alkynyloxy, optionally substituted C 2 -C 10 heteroalkyloxy, optionally substituted C 3 -C 12 cycloalkyloxy, optionally substituted C 3 -C 12 cycloalkenyloxy, optionally substituted C 2 -C 12 heterocycloalkyloxy, optionally substituted C 2 -C 12 heterocycloalkenyloxy, optionally substituted C 6 -C 18 aryloxy, optionally substituted C 1 -C 18 heteroaryloxy and optionally substituted C 1 -C 12 alkylamino; R 2 and R 3 are each independently selected from the group consisting of H and C 1 -C 12 alkyl; R 4 and R 5 are each independently selected from the group consisting of H, and C 1 -C 20 alkyl, n is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20; X − is a counterion; and subjecting the unsaturated amine salt to cross-metathesis with a compound of Formula II wherein R 7 is selected from the group consisting of OH, OR 7a and NR 7a R 7b ; R 8 is selected from the group consisting of H and C 1 -C 12 alkyl; R 9 and R 10 are each independently selected from the group consisting of H, C 1 -C 12 alkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl and C(═O)R 7 ; and R 7 and R 7b are each independently selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 2 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 2 -C 12 heterocycloalkenyl, optionally substituted C 6 -C 18 aryl, optionally substituted C 1 -C 18 heteroaryl, optionally substituted C 1 -C 12 alkyloxy, optionally substituted C 2 -C 12 alkenyloxy, optionally substituted C 2 -C 12 alkynyloxy, optionally substituted C 2 -C 10 heteroalkyloxy, optionally substituted C 3 -C 12 cycloalkyloxy, optionally substituted C 3 -C 12 cycloalkenyloxy, optionally substituted C 2 -C 12 heterocycloalkyloxy, optionally substituted C 2 -C 12 heterocycloalkenyloxy, optionally substituted C 6 -C 18 aryloxy, optionally substituted C 1 -C 18 heteroaryloxy and optionally substituted C 1 -C 12 alkylamino; in the presence of a metathesis catalyst to give the amino acid salt or derivative thereof. 2. The process according to claim 1 , wherein R 1 is H, R 2 is H and R 3 is H. 3. The process according to claim 1 , wherein n is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. 4. The process according to claim 1 , wherein R 4 is H and R 5 is H. 5. The process according to claim 1 , wherein X − is selected from the group consisting of BF 4 − , TsO − , Cl − , TfO − , TFA − , Adipate 2− , BSA − , MsO − , HSO 4 − , F − , Br − , I − , H 2 AsO 4 − , H 2 PO 4 − , H 2 AsO 3 − , HPO 4 2− , H 2 PO 4 − , SO 4 2− , NO 3 − , NO 2 − , S 2 O 3 2− , HSO 3 − , ClO 4 − , IO 3 − , ClO 3 − , BrO 3 − , ClO 2 − , CrO 4 2− , HCO 3 − , Cr 2 O 7 2− , ClCH 2 COO − , HCOO − , OCN − , HC 2 O 4 − , B(OR) 4 − , B(OH) 4 − , CF 2 HSO 2 —O − , CFH 2 SO 2 —O − and alkyl aryl sulfonates. 6. The process according to claim 5 , wherein X − is selected from the group consisting of BF 4 − , TsO − and TfO − . 7. The process according to claim 1 , wherein R 7 is selected from the group consisting of OH and OC 1 -C 6 alkyl. 8. The process according to claim 1 , wherein R 8 is H, R 9 is H and R 10 is H. 9. The process according to claim 1 , wherein the compound of Formula II is a compound of Formula III wherein R 7 is selected from the group consisting of OH, OR 7a and NR 7a R 7b ; and R 7a and R 7b are each independently selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 2 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 3 -C 12 cycloalkenyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 2 -C 12 heterocycloalkenyl, optionally substituted C 6 -C 18 aryl, optionally substituted C 1 -C 18 heteroaryl, optionally substituted C 1 -C 12 alkyloxy, optionally substituted C 2 -C 12 alkenyloxy, optionally substituted C 2 -C 12 alkynyloxy, optionally substituted C 2 -C 10 heteroalkyloxy, optionally substituted C 3 -C 12 cycloalkyloxy, optionally substituted C 3 -C 12 cycloalkenyloxy, optionally substituted C 2 -C 12 heterocycloalkyloxy, optionally substituted C 2 -C 12 heterocycloalkenyloxy, optionally substituted C 6 -C 18 aryloxy, optionally substituted C 1 -C 18 heteroaryloxy and optionally substituted C 1 -C 12 alkylamino. 10. A process according to claim 1 , wherein the catalyst is a metal complex wherein the metal in the metal complex is selected from the group consisting of ruthenium, molybdenum and tungsten. 11. A process according to claim 1 , wherein the catalyst is a ruthenium-alkylidene catalyst, a Grubbs catalyst or a later generation analogue, or a Hoveyda Grubbs second generation catalyst. 12. The process according claim 1 , further comprising the step of hydrogenating the amino acid salt or derivative thereof; formed from cross-metathesis to give a saturated amino acid salt. 13. The process according to claim 12 , wherein the cross-metathesis step and the hydrogenating step are performed in series without isolation of the amino acid salt or derivative thereof; after cross-metathesis.
Reduction · CPC title
by reactions not involving the amino or carboxyl groups · CPC title
Preparation from compounds containing pyridine rings · CPC title
Isomerisation · CPC title
from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.